Stryjek-Kamińska D, Malczewski B, Kopeć A, Rowińska-Marcińska K
Department of Gastroenterology and Metabolic Diseases, Medical Academy, Warsaw, Poland.
Acta Diabetol Lat. 1988 Jan-Mar;25(1):41-8. doi: 10.1007/BF02581244.
The purpose of this study was to establish the correlation between the genetically determined rate of acetylation of certain drugs and the development of diabetic neuropathy. Acetylator phenotype was determined according to Evans in 100 healthy individuals and 160 diabetics including 80 patients with type I and 80 with type II diabetes. The diagnosis of diabetic neuropathy was based on clinical neurological examination. In addition, electrostimulation was carried out in 49 diabetics. Among the healthy controls, the fast acetylator phenotype was found in 44 cases (44%) and the slow one in 56 (56%). In type I diabetes these values were 51 (64%) and 29 (36%), in type II 46 (58%) and 34 (42%), respectively. The predominance of fast acetylators in type I diabetes was statistically significant (p less than 0.01) when compared to the healthy population of Warsaw. However, no significant correlation was found between diabetic neuropathy and the distribution of acetylator phenotype. Further prospective studies are necessary in order to ascertain whether the acetylator phenotype might be considered a genetic marker of type I diabetes.
本研究的目的是确定某些药物的基因决定的乙酰化速率与糖尿病神经病变发展之间的相关性。根据埃文斯的方法，对100名健康个体和160名糖尿病患者（包括80名I型糖尿病患者和80名II型糖尿病患者）进行乙酰化表型测定。糖尿病神经病变的诊断基于临床神经学检查。此外，对49名糖尿病患者进行了电刺激。在健康对照组中，发现44例（44%）为快速乙酰化表型，56例（56%）为慢速乙酰化表型。在I型糖尿病中，这些值分别为51例（64%）和29例（36%），在II型糖尿病中分别为46例（58%）和34例（42%）。与华沙的健康人群相比，I型糖尿病中快速乙酰化者占优势具有统计学意义（p小于0.01）。然而，未发现糖尿病神经病变与乙酰化表型分布之间存在显著相关性。为了确定乙酰化表型是否可被视为I型糖尿病的遗传标志物，有必要进行进一步的前瞻性研究。
